EXECUTIVE SUMMARY

Compassionate Certification Centers (CCC or We) is a full-service medical cannabis healthcare network which operates both intra-state and virtually in Pennsylvania. Pennsylvania is the fifth largest market potential in the United States due to the number of permitted medical conditions. CCC is a first of its kind medical cannabis organization poised to become a country-wide medical cannabis healthcare system. Able to ship to and operate in all states that have legalized medical cannabis, without touching the plant CCC is able to tap into the total medical cannabis market, which has a three-year projection of 1.3-billion-dollars. We lead and service within the medical cannabis industry, and with the 2018 Farm Bill as its sail, the U.S. hemp market will expand to lead the global hemp industry by 2020, representing 32% of a 5.7 billion dollar global market.

Founded and operated by physicians, CCC is devoted to assisting patients and clients with the integration of medical cannabis treatment options, including cannabidiol (CBD) derived from hemp, into their care plan and lifestyle.

Foundation:
CCC has spent the last three years building a strong nationally recognized foundation in the medical cannabis market, led via the initiation and ongoing success of our trademarked World Medical Cannabis Conference and Expo currently entering its third year of operation. Our landmark event has served to build our three revenue streams, medical cannabis certifications, CBD, and clinical research trials. Moving forward, it will continue to be a platform for building brand recognition, education, sales, and ensuring appropriate market share and exposure.

CCC’s core business operations involve “brick & mortar” medical offices that are currently located throughout the state of Pennsylvania. These offices are the first touch point to all medical cannabis patients/clients in the United States market. Over 1.5 million people currently have a medical marijuana card in the United States, and CCC’s unique composition serves to support these patients with their medical marijuana treatment plan, and specifically help patients obtain their medical marijuana certifications (and recertification each year for residual income). Our centers are staffed by board certified, multi-specialty physicians, all officially credentialed to evaluate and issue state level medical marijuana patient certifications. To date, CCC has certified over 10,000 patients in Pennsylvania over the course of the state’s initial year of program operations, opened more than 10 state-wide locations and has become the premier medical cannabis organization in
Pennsylvania. Plans for aggressive expansion, both inside Pennsylvania and to other states, are on the horizon for late 2019 and beyond.

In addition to our core medical certification business model, CCC has expanded to offer two additional, patient and industry focused specialty areas, to both meet demand and diversify, while at the same time providing further significant revenue streams.

**CBD:**
The first of these processes was integration of hemp derived CBD based products into CCC’s core business model. During the past calendar year, in order to provide our patients with access to medical cannabis-based therapy, CBD has been integrated into our doctors’ visits and routine with each patient evaluation. Based on an overwhelming response and thus opportunity, we have since developed our own well known, trademarked and branded CCC white labeled line of CBD products, for which we have already had tremendous success.

We feel that CCC is uniquely positioned in the CBD market as we have medical grade CBD, third party credibility, triple lab tested products and we are an organization led by physicians and healthcare providers. This gives us a large and definitive advantage over most of our competitors, with over 26,000 patients registered in our database to become a patient or to come back for yearly re-certifications and follow-ups. We foresee CCC labeled CBD products and sales leading the way for our organization moving forward.

**Research:**
Similar to our position with CBD, because of CCC’s physician leadership and patient base, we have already uniquely positioned and executed on the integration of clinical research (trials, studies, product R&D) into our clinical practice and business model. Our current patient base needing medical cards, as well as CBD purchases and consults, makes these patients readily available to fill research trials, which increases revenue, data acquisition, sales, and brand recognition.

**Management Team:**
Two of our lead physicians, Dr. Bryan Doner and Dr. Keyur Patel, have over 15 years combined clinical research experience with numerous published articles. Additionally, CEO Melonie Kotchey also has several years of experience working in the clinical trials space obtaining research grants from large academic institutions, totaling over 50 million dollars. Our clinical research experience, coupled with CCC’s vast patient access and database, combine for a tremendous opportunity on the research front. Not only to further place CCC as an industry leader, but also to provide a significant source of ongoing revenue in the future, as regardless of legislation, research will continue to thrive and expand.
CCC has recently entered into our first official clinical trial, to study the effects of CBD on Irritable Bowel Syndrome. In addition, CCC will initiate its own internal Research Division for which we expect rapid growth and expansion into numerous other clinical trials and projects moving forward.

In summary, CCC is the first of its kind, physician initiated and operated, medical cannabis ancillary organization. Our brick and mortar offices serve as the foundation of our US medical cannabis healthcare business model and have helped us develop a patient base into the tens of thousands, while rapidly expanding our footprint across Pennsylvania. Integration of our own profitable white labeled brand of CBD has offered an additional tremendous treatment option and revenue stream, and is set-up to grow exponentially in the near future. The research arm of CCC will be the integration of CBD and clinical research into our operations model, and deployment of a low cost, large scale CBD sales strategy.

www.CompassionateCertificationCenters.com